A Phase 2/3 Study Of Brepocitinib In Adults With Lichen Planopilaris

Overview

About this study

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with lichen planopilaris

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

1. Age ≥ 18 years
2. Scalp biopsy consistent with LPP
3. Active and symptomatic LPP at screening and baseline-
4. Weight > 40 kg to < 130 kg with BMI ≤ 45 kg/m2

Exclusion Criteria:

1. History of: Lymphoproliferative disorder; Active malignancy; History of cancer within 5 years prior to baseline (exceptions for basal cell carcinoma, squamous cell carcinoma, ductal carcinoma in situ of the breast, carcinoma in situ of the uterine cervix, or thyroid cancer).
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 08/26/2026. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Aaron Mangold, M.D.

Open for enrollment

Contact information:

Samantha Devlin

(480) 342-2906

cosby.samantha@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20597996

Mayo Clinic Footer